Keep an eye on Carefully (1)pentobarbital will decrease the level or effect of mifepristone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. CYP3A4 inducers haven't been examined, coadministration not advised by company

pentobarbital will decrease the extent or effect of tadalafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Keep away from combination in pulmonary HTN patients. For sufferers with ED, observe response to tadalafil meticulously as a result of opportunity for lessened performance.

pentobarbital will lower the extent or influence of estrogens esterified by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will minimize the extent or result of dutasteride by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.

pentobarbital will reduce the level or impact of tacrolimus by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.

pentobarbital will decrease the extent or result of vincristine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.

pentobarbital will reduce the level or result of osilodrostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will more info minimize the extent or impact of finasteride by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Mysterious.

pentobarbital will minimize the level or effect of sufentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.

pentobarbital will lessen the extent or effect of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.

With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.

Contraindicated (1)pentobarbital will minimize the extent or result of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a delicate CYP3A4 substrate. Coadministration with robust or moderate CYP3A4 inducers is contraindicated.

If unable to avoid, double existing pralsetinib dose starting off on Day 7 of coadministration with solid CYP3A inducer. Following inducer has actually been discontinued for a minimum of 14 times, resume past pralsetinib dose.

pentobarbital will reduce the level or impact of brexpiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Double brexpiprazole dose more than 1-two months if administered with a solid CYP3A4 inducer.